Related Experiment Video

Updated: Jun 3, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.0K

Neoadjuvant Targeted Therapy in Non-Small Cell Lung Cancer and Its Impact on Surgical Outcomes

Mark Sorin1,2, Caroline Huynh1,3, Merav Rokah3

  • 1Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montréal, Quebec, Canada.

Annals of Thoracic Surgery Short Reports
|January 10, 2025
PubMed
Abstract

Insights

Neoadjuvant targeted therapy for non-small cell lung cancer (NSCLC) shows potential but requires further study. This approach impacts surgical outcomes and the overall patient experience, highlighting the need for careful consideration in treatment planning.

Area of Science:

  • Oncology
  • Thoracic Surgery
  • Pharmacology

Background:

  • Limited evidence exists for neoadjuvant targeted therapy in non-small cell lung cancer (NSCLC).
  • Currently, two phase 3 trials are recruiting, and no indications are approved for this treatment strategy.

Purpose of the Study:

  • To describe clinical experience with neoadjuvant targeted therapy in operable non-small cell lung cancer (NSCLC).
  • To highlight the importance of surgical outcomes as an underreported aspect of neoadjuvant therapy in NSCLC.

Main Methods:

  • Retrospective review of patients with operable non-small cell lung cancer (NSCLC) who received neoadjuvant targeted therapy.
  • Analysis of surgical outcomes, including potential benefits and risks associated with the therapy.

Main Results:

  • Surgical outcomes are a critical, yet underreported, component of neoadjuvant targeted therapy for non-small cell lung cancer (NSCLC).
  • The application of neoadjuvant targeted therapy presents both significant potential benefits and risks impacting surgical planning and execution.

Conclusions:

  • Neoadjuvant targeted therapy significantly influences the patient experience in non-small cell lung cancer (NSCLC) treatment.
  • The impact on surgical planning, strategy, and outcomes necessitates careful evaluation for optimal patient care.

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.4K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

381

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K